Results 121 to 130 of about 5,702,542 (372)

The Super Enhancer‐Driven Long Noncoding RNA PRKCQ‐AS1 Promotes Neuroblastoma Tumorigenesis by Interacting With MSI2 Protein and Is Targetable by Small Molecule Compounds

Advanced Science, EarlyView.
PRKCQ‐AS1 is overexpressed due to transcriptional super‐enhancers. PRKCQ‐AS1 RNA forms a complex with MSI2 protein to induce BMX mRNA stabilization and overexpression, ERK protein phosphorylation and neuroblastoma cell proliferation. Compound NSC617570 blocks PRKCQ‐AS1 binding to MSI2, leading to BMX mRNA disassociation from MSI2 protein, BMX reduction,
Sujanna Mondal, Pei Y. Liu, Janith Seneviratne, Antoine De Weck, Pooja Venkat, Chelsea Mayoh, Jing Wu, Jesper Maag, Jingwei Chen, Matthew Wong, Nenad Bartonicek, Poh Khoo, Lei Jin, Louise E. Ludlow, David S. Ziegler, Toby Trahair, Pieter Mestdagh, Belamy B. Cheung, Jinyan Li, Marcel E. Dinger, Ian Street, Xu D. Zhang, Glenn M. Marshall, Tao Liu   +23 more
wiley   +1 more source

The protective effects of rutin on the liver, kidneys, and heart by counteracting organ toxicity caused by synthetic and natural compounds

Food Science &Nutrition, Volume 11, Issue 1, Page 39-56, January 2023., 2023
Rutin is a flavonoid present in many plant species. Because of its antioxidant, anti‐inflammatory, and anti‐apoptotic properties, rutin is of interest for its potential protective effects against toxic agents. Rutin has potential therapeutic effectiveness against several toxicants, and its beneficial effects are more than likely mediated by its ...
Sohrab Rahmani, Karim Naraki, Ali Roohbakhsh, A. Wallace Hayes, Gholamreza Karimi   +4 more
wiley   +1 more source

Unlocking the therapeutic potential of selective CDK7 and BRD4 Inhibition against multiple myeloma cell growth

Haematologica
Multiple myeloma (MM) is a plasma cell malignancy considered incurable despite the recent therapeutic advances. Effective targeted therapies are therefore needed.
Yao Yao, Shuhui Deng, Jessica Fong Ng, Mei Yuan, Chandraditya Chakraborty, Vera JoyWeiler, Nikhil Munshi, Mariateresa Fulciniti   +7 more
doaj   +1 more source

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

New England Journal of Medicine, 2016
BACKGROUND Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma. METHODS In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 722 patients who had relapsed, refractory ...
P. Moreau, T. Masszi, N. Grząśko, N. Bahlis, M. Hansson, L. Pour, I. Sandhu, P. Ganly, B. Baker, S. Jackson, A. Stoppa, D. Simpson, P. Gimsing, A. Palumbo, L. Garderet, M. Cavo, Shaji K. Kumar, C. Touzeau, F. Buadi, J. Laubach, D. Berg, Jianchang Lin, A. Di Bacco, A. Hui, H. V. D. van de Velde, P. Richardson   +25 more
semanticscholar   +1 more source

Advancing Allogeneic NK Cell Immunotherapy through Microfluidic Gene Delivery

Advanced Science, EarlyView.
The Y‐Hydroporator is a microfluidic gene delivery platform designed for allogeneic NK cell‐based immunotherapies. It achieves highly efficient gene delivery while preserving high cell viability and functionality. By producing engineered NK cells with enhanced cytotoxicity, the platform addresses critical limitations of autologous cell therapy ...
Hyelee Kim, Mujin Lee, Bohwa Han, Jinho Kim, Duck Cho, Junsang Doh, Aram J. Chung   +6 more
wiley   +1 more source

TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation

Hepatology, EarlyView., 2022
Abstract Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets.
Yuto Shiode, Takahiro Kodama, Satoshi Shigeno, Kazuhiro Murai, Satoshi Tanaka, Justin Y. Newberg, Jumpei Kondo, Shogo Kobayashi, Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Hiroshi Suemizu, Tomohide Tatsumi, Hidetoshi Eguchi, Nancy A. Jenkins, Neal G. Copeland, Tetsuo Takehara   +16 more
wiley   +1 more source

A CLDN18.2‐Targeted Nanoplatform Manipulates Magnetic Hyperthermia Spatiotemporally for Synergistic Immunotherapy in Gastric Cancer

Advanced Science, EarlyView.
CLDN18.2 is a highly selective biomarker exposed in gastric cancer. A CLDN18.2‐specific antibody 1D5 conjugated fluorescence‐magnetic nanoparticle is developed for image‐guided precision theragnostics. Under the assistance of sensitive FMI and deep‐penetrating MPI for tracing and timing the optimal nanoparticle dosage, combining α‐PD1 therapy with ...
Xueying Wang, Hui Hui, Jing Han, Ting Guo, Yiding Wang, Lin Meng, Cong Chen, Jie He, Xiaoyong Guo, Fuyu Zhong, Hong Du, Jie Tian, Xiaofang Xing, Yang Du, Jiafu Ji   +14 more
wiley   +1 more source

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis

Hematological Oncology, Volume 40, Issue 5, Page 1020-1029, December 2022., 2022
Abstract In this subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285), we evaluated efficacy and safety of the anti‐CD38 monoclonal antibody isatuximab (Isa) in combination with carfilzomib‐dexamethasone (Isa‐Kd) versus Kd in older (≥70 years of age, n = 86) and younger (<70 years, n = 216) patients with relapsed multiple myeloma (MM).
Thierry Facon, Philippe Moreau, Thomas G. Martin, Ivan Spicka, Albert Oriol, Youngil Koh, Andrew Lim, Gabor Mikala, Laura Rosiñol, Münci Yağci, Michele Cavo, Kwee Yong, Marie‐Laure Risse, Gaëlle Asset, Sandrine Schwab, Gracia Martinez   +15 more
wiley   +1 more source

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

New England Journal of Medicine, 2018
BACKGROUND The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma.
M. Dimopoulos, D. Dytfeld, S. Grosicki, P. Moreau, N. Takezako, M. Hori, X. Leleu, R. LeBlanc, Kenshi Suzuki, M. Raab, P. Richardson, Mihaela Popa Mckiver, Ying‐Ming Jou, S. Shelat, Michael D. Robbins, B. Rafferty, J. San-Miguel   +16 more
semanticscholar   +1 more source

Enhancer Extrachromosomal Circular DNA ANKRD28 Elicits Drug Resistance via POU2F2‐Mediated Transcriptional Network in Multiple Myeloma

Advanced Science, EarlyView.
Enhancer eccANKRD28‐manipulated MM cells have been demonstrated to facilitate drug resistance and promote MM progression by activating the key transcription factor, POU2F2. POU2F2 interacts with sequence‐specific eccANKRD28 as well as RUNX1 and RUNX2 motifs to form the protein complex, which activates the promoter of oncogenes (IRF4, JUNB, IKZF3, et al.
Binzhen Chen, Jia Liu, Yaoxin Zhang, Changming Shi, Di Zhu, Guoqiang Zhang, Fei Xiao, Lu Zhong, Minyue Zhang, Lai Guan Ng, Honghui Huang, Tingting Lu, Jian Hou   +12 more
wiley   +1 more source